Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael P Fautsch

Showing results (91-100 of 112) with videos related to

Pageof 12
Sort By:
Current Eye Research|November 19, 2019
Diet Mimicking "Fast Food" Causes Structural Changes to the Retina Relevant to Age-Related Macular DegenerationGavin W Roddy, Robert H Rosa, Kimberly B Viker, et al.
Molecular Vision|April 20, 2004
Long-term retinal transgene expression with FIV versus adenoviral vectorsNils Loewen, David A Leske, J Douglas Cameron, et al.
Investigative Ophthalmology & Visual Science|May 25, 2017
Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure-Lowering Effects of LatanoprostGavin W Roddy, Kimberly B Viker, Nelson S Winkler, et al.
BMJ Open Ophthalmology|May 15, 2025
Associations between measures of oestrogen exposure and severity of Fuchs endothelial corneal dystrophyRedion B Petrela, Chandra Divyash Chhetri, Ahmad Najafi, et al.
Current Eye Research|July 18, 2019
Stanniocalcin-1 is a Modifier of Oxygen-Induced Retinopathy SeverityLauren A Dalvin, Mary Elizabeth Hartnett, Colin A Bretz, et al.
Plos One|April 17, 2020
Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbitsUttio Roy Chowdhury, Rachel A Kudgus, Tommy A Rinkoski, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|May 18, 2023
Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive AgentUttio Roy Chowdhury, Cynthia L Pervan-Steel, Ryan Sheeler, et al.
Cornea|March 30, 2021
Relationship of Body Mass Index With Fuchs Endothelial Corneal Dystrophy Severity and TCF4 CTG18.1 Trinucleotide Repeat ExpansionBhumi B Kinariwala, Timothy T Xu, Keith H Baratz, et al.
Plos One|September 29, 2021
Characterization of a dual media system for culturing primary normal and Fuchs endothelial corneal dystrophy (FECD) endothelial cellsTommy A Rinkoski, Cindy K Bahler, Johann M Pacheco, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|March 30, 2021
Pharmacological Profile and Ocular Hypotensive Effects of Cromakalim Prodrug 1, a Novel ATP-Sensitive Potassium Channel Opener, in Normotensive Dogs and Nonhuman PrimatesUttio Roy Chowdhury, Rachel A Kudgus, Bradley H Holman, et al.
Pageof 12

Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Current Eye Research|November 19, 2019
Diet Mimicking "Fast Food" Causes Structural Changes to the Retina Relevant to Age-Related Macular DegenerationGavin W Roddy, Robert H Rosa, Kimberly B Viker, et al.
Molecular Vision|April 20, 2004
Long-term retinal transgene expression with FIV versus adenoviral vectorsNils Loewen, David A Leske, J Douglas Cameron, et al.
Investigative Ophthalmology & Visual Science|May 25, 2017
Stanniocalcin-1 Is an Ocular Hypotensive Agent and a Downstream Effector Molecule That Is Necessary for the Intraocular Pressure-Lowering Effects of LatanoprostGavin W Roddy, Kimberly B Viker, Nelson S Winkler, et al.
BMJ Open Ophthalmology|May 15, 2025
Associations between measures of oestrogen exposure and severity of Fuchs endothelial corneal dystrophyRedion B Petrela, Chandra Divyash Chhetri, Ahmad Najafi, et al.
Current Eye Research|July 18, 2019
Stanniocalcin-1 is a Modifier of Oxygen-Induced Retinopathy SeverityLauren A Dalvin, Mary Elizabeth Hartnett, Colin A Bretz, et al.
Plos One|April 17, 2020
Pharmacological and pharmacokinetic profile of the novel ocular hypotensive prodrug CKLP1 in Dutch-belted pigmented rabbitsUttio Roy Chowdhury, Rachel A Kudgus, Tommy A Rinkoski, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|May 18, 2023
Preclinical Pharmacokinetic Profile of Topical Ophthalmic and Intravenous Delivery of QLS-101, a Novel ATP-Sensitive Potassium Channel Opening Ocular Hypotensive AgentUttio Roy Chowdhury, Cynthia L Pervan-Steel, Ryan Sheeler, et al.
Cornea|March 30, 2021
Relationship of Body Mass Index With Fuchs Endothelial Corneal Dystrophy Severity and TCF4 CTG18.1 Trinucleotide Repeat ExpansionBhumi B Kinariwala, Timothy T Xu, Keith H Baratz, et al.
Plos One|September 29, 2021
Characterization of a dual media system for culturing primary normal and Fuchs endothelial corneal dystrophy (FECD) endothelial cellsTommy A Rinkoski, Cindy K Bahler, Johann M Pacheco, et al.
Journal of Ocular Pharmacology and Therapeutics : the Official Journal of the Association for Ocular Pharmacology and Therapeutics|March 30, 2021
Pharmacological Profile and Ocular Hypotensive Effects of Cromakalim Prodrug 1, a Novel ATP-Sensitive Potassium Channel Opener, in Normotensive Dogs and Nonhuman PrimatesUttio Roy Chowdhury, Rachel A Kudgus, Bradley H Holman, et al.
Pageof 12